Published in Mol Cancer Res on August 04, 2011
Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res (2013) 1.16
CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle (2012) 1.12
The p57 CDKi integrates stress signals into cell-cycle progression to promote cell survival upon stress. EMBO J (2012) 1.12
CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle (2013) 0.99
Gain of function in CDKN1C. Nat Genet (2012) 0.92
Maternal-fetal conflict, genomic imprinting and mammalian vulnerabilities to cancer. Philos Trans R Soc Lond B Biol Sci (2015) 0.91
Beckwith-Wiedemann and IMAGe syndromes: two very different diseases caused by mutations on the same gene. Appl Clin Genet (2014) 0.86
Paternal deletion of the 11p15.5 centromeric-imprinting control region is associated with alteration of imprinted gene expression and recurrent severe intrauterine growth restriction. J Med Genet (2012) 0.84
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood (2016) 0.82
A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases. Epigenetics Chromatin (2014) 0.82
Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. Neuro Oncol (2013) 0.81
p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance. Oncogene (2014) 0.80
Cancer cell-selective killing polymer/copper combination. Biomater Sci (2015) 0.77
Lhx6 and Lhx8 promote palate development through negative regulation of a cell cycle inhibitor gene, p57Kip2. Hum Mol Genet (2015) 0.77
Cellular Response upon Stress: p57 Contribution to the Final Outcome. Mediators Inflamm (2015) 0.76
Defective pericyte recruitment of villous stromal vessels as the possible etiologic cause of hydropic change in complete hydatidiform mole. PLoS One (2015) 0.76
Histone Deacetylase Inhibitors Increase p27(Kip1) by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation. Oxid Med Cell Longev (2015) 0.75
The role of cytoplasmic p57 in invasion of hepatocellular carcinoma. BMC Gastroenterol (2015) 0.75
Upregulation of cyclin-dependent kinase inhibitors CDKN1B and CDKN1C in hepatocellular carcinoma-derived cells via goniothalamin-mediated protein stabilization and epigenetic modifications. Toxicol Rep (2015) 0.75
CDK inhibitors for muscle stem cell differentiation and self-renewal. J Phys Fit Sports Med (2017) 0.75
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood (2011) 2.29
Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. Nat Genet (2009) 2.12
Mutational spectrum in congenital dyserythropoietic anemia type II: identification of 19 novel variants in SEC23B gene. Am J Hematol (2010) 1.60
Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood (2003) 1.58
Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet (2011) 1.37
p27Kip1 metabolism: a fascinating labyrinth. Cell Cycle (2007) 1.34
Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster. Blood (2005) 1.26
Resveratrol: from basic science to the clinic. Cell Cycle (2007) 1.23
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood (2011) 1.23
Molecular analysis of 42 patients with congenital dyserythropoietic anemia type II: new mutations in the SEC23B gene and a search for a genotype-phenotype relationship. Haematologica (2009) 1.20
Red blood cell membrane defects. Rev Clin Exp Hematol (2003) 1.19
p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem (2003) 1.19
Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat (2013) 1.18
Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. J Clin Invest (2014) 1.13
Targeting p27Kip1 protein: its relevance in the therapy of human cancer. Expert Opin Ther Targets (2011) 1.07
Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation (2013) 1.06
The N-terminal 11 amino acids of human erythrocyte band 3 are critical for aldolase binding and protein phosphorylation: implications for band 3 function. Blood (2005) 1.02
Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation). Haematologica (2011) 1.02
The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. Bone (2011) 1.01
Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem (2003) 1.00
Retinoic acid induces p27Kip1 nuclear accumulation by modulating its phosphorylation. Cancer Res (2006) 0.99
ROBO2 gene variants are associated with familial vesicoureteral reflux. J Am Soc Nephrol (2008) 0.98
PTPepsilon has a critical role in signaling transduction pathways and phosphoprotein network topology in red cells. Proteomics (2008) 0.96
Frequency of congenital dyserythropoietic anemias in Europe. Eur J Haematol (2010) 0.94
Resveratrol: from basic studies to bedside. Cancer Treat Res (2014) 0.94
A genome search for primary vesicoureteral reflux shows further evidence for genetic heterogeneity. Pediatr Nephrol (2008) 0.90
Membrane association of peroxiredoxin-2 in red cells is mediated by the N-terminal cytoplasmic domain of band 3. Free Radic Biol Med (2012) 0.90
Reliability of EMA binding test in the diagnosis of hereditary spherocytosis in Italian patients. Acta Haematol (2010) 0.90
Biological response of human bone marrow mesenchymal stem cells to fluoride-modified titanium surfaces. Clin Oral Implants Res (2010) 0.89
Caspase 3 and 8 deficiency in human neuroblastoma. Cancer Genet Cytogenet (2003) 0.89
CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura. Haematologica (2011) 0.89
Congenital dyserythropoietic anemia type II: exclusion of seven candidate genes. Blood Cells Mol Dis (2003) 0.88
In vivo effect of the natural antioxidant hydroxytyrosol on cyclosporine nephrotoxicity in rats. Nephrol Dial Transplant (2007) 0.88
Spectrum of FANCA mutations in Italian Fanconi anemia patients: identification of six novel alleles and phenotypic characterization of the S858R variant. Hum Mutat (2003) 0.88
P27Kip1 serine 10 phosphorylation determines its metabolism and interaction with cyclin-dependent kinases. Cell Cycle (2014) 0.88
Retinoic acid inhibits the growth of bone marrow mesenchymal stem cells and induces p27Kip1 and p16INK4A up-regulation. Mol Cell Biochem (2003) 0.88
Renal hypoplasia without optic coloboma associated with PAX2 gene deletion. Nephrol Dial Transplant (2007) 0.88
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PLoS One (2011) 0.87
The effects of titanium nitride-coating on the topographic and biological features of TPS implant surfaces. J Dent (2011) 0.86
Congenital dyserythropoietic anemia type II: molecular analysis and expression of the SEC23B gene. Orphanet J Rare Dis (2011) 0.86
EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One (2010) 0.85
Splenectomy prolongs in vivo survival of erythrocytes differently in spectrin/ankyrin- and band 3-deficient hereditary spherocytosis. Blood (2002) 0.85
Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major. Am J Hematol (2014) 0.85
Bone marrow mesenchymal stem cell response to nano-structured oxidized and turned titanium surfaces. Clin Oral Implants Res (2011) 0.84
Proliferate and survive: cell division cycle and apoptosis in human neuroblastoma. Haematologica (2002) 0.84
Diverse effects of natural antioxidants on cyclosporin cytotoxicity in rat renal tubular cells. Nephrol Dial Transplant (2005) 0.84
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. Carcinogenesis (2010) 0.84
Cystatin B and its EPM1 mutants are polymeric and aggregate prone in vivo. Biochim Biophys Acta (2007) 0.83
Beta-spectrinBari: a truncated beta-chain responsible for dominant hereditary spherocytosis. Haematologica (2009) 0.83
Abnormalities of erythrocyte glycoconjugates are identical in two families with congenital dyserythropoietic anemia type II with different chromosomal localizations of the disease gene. Haematologica (2007) 0.83
The HIF2A gene in familial erythrocytosis. N Engl J Med (2008) 0.82
Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor. Carcinogenesis (2008) 0.82
Splenectomy for hereditary spherocytosis: complete, partial or not at all? Expert Rev Hematol (2011) 0.82
Erythropoietin receptors on cancer cells: a still open question. J Clin Oncol (2007) 0.82
Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen. Br J Haematol (2002) 0.82